Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
Portfolio Pulse from Benzinga Newsdesk
Intercept Pharmaceuticals announced new results from a planned interim analysis of its ongoing Phase 2 study 747-213, showing that the combination of obeticholic acid (OCA) and bezafibrate was effective in normalizing multiple biochemical markers associated with PBC-induced liver damage.
June 23, 2023 | 7:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intercept Pharmaceuticals' Phase 2 study of OCA-bezafibrate combination shows promising results in treating PBC-induced liver damage, potentially boosting the company's stock.
The positive interim results from Intercept Pharmaceuticals' ongoing Phase 2 study indicate that the OCA-bezafibrate combination is effective in treating PBC-induced liver damage. This news is likely to be well-received by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100